These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28730751)

  • 21. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations.
    Iannone F; Cantini F; Lapadula G
    J Rheumatol Suppl; 2014 May; 91():41-6. PubMed ID: 24788999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
    Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
    Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
    Pettipher C; Benitha R
    Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents: A National and International Survey of Rheumatologists.
    Tran NQ; Garcia-Rosell M; Pattanaik D; Raza SH; Carbone L
    J Clin Rheumatol; 2017 Jan; 23(1):6-11. PubMed ID: 28002150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does chronic immunosuppressive therapy for autoimmune disease influence the risk of developing active tuberculosis?
    Bardazzi F; Leuzzi M; Ferrara F; Patrizi A; Loi C
    Dermatol Ther; 2019 Jan; 32(1):e12777. PubMed ID: 30371983
    [No Abstract]   [Full Text] [Related]  

  • 29. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis.
    Chen DY; Shen GH; Chen YM; Chen HH; Lin CC; Hsieh CW; Lan JL
    Int J Tuberc Lung Dis; 2011 Feb; 15(2):192-200. PubMed ID: 21219680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Latent tuberculosis infection in patients with rheumatic diseases.
    Anton C; Machado FD; Ramirez JMA; Bernardi RM; Palominos PE; Brenol CV; Mello FCQ; Silva DR
    J Bras Pneumol; 2019 Apr; 45(2):e20190023. PubMed ID: 31038654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycobacterium tuberculosis: Active disease and latent infection in a renal transplant cohort.
    Rafiei N; Williams J; Mulley WR; Trauer JM; Jenkin GA; Rogers BA
    Nephrology (Carlton); 2019 May; 24(5):569-574. PubMed ID: 29660203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M
    Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Latent tuberculosis infection (LTBI): a real host defence or a permanent threat?
    Sanduzzi A; Ponticiello A; Bocchino M; Perna F; Vatrella A
    Infez Med; 2016 Sep; 24(3):179-82. PubMed ID: 27668896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
    Haukaas FS; Arnesen TM; Winje BA; Aas E
    Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis.
    Cuomo G; D’Abrosca V; Iacono D; Pantano I
    Clin Rheumatol; 2017 Feb; 36(2):457-461. PubMed ID: 27817127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Screening for tuberculosis before TNFα treatment in routine rheumatic care in Iceland. Result from the nationwide ICEBIO registry].
    Bjorgulfsson TM; Gröndal G; Blondal T; Gudbjornsson B
    Laeknabladid; 2018 Mai; 104(5):231-235. PubMed ID: 29717989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
    J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.